References
- Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996;23:454–61.
- Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, . 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–51.
- Pai H, Hong JY, Byeon JH, Kim YK, Lee HJ. High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2004;48: 3159–61.
- Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:338–48.
- Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, . High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 2006;12:56–62.
- Thomson KS, Moland ES. Cefepime, piperacillin–tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548–54.
- Kang CI, Pai H, Kim SH, Kim HB, Kim EC, Oh MD, . Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother 2004;54:1130–3.